Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VBI Vaccines Inc VBIV

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.


NDAQ:VBIV - Post by User

VBI Vaccines Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Poorcharlieon Sep 20, 2019 11:38am
146 Views
Post# 30148000

RE:RE:RE:RE:VBIV .70~NASDAQ~ FORM 4 INSIDER FILING OUT!!!

RE:RE:RE:RE:VBIV .70~NASDAQ~ FORM 4 INSIDER FILING OUT!!!"Now" the insiders will load up. The stock runs down, management issues more stock at the bottom. Would not be surprised to see options issued along with management putting in their own in at this time. Would be interesting to see who sold a lot of stock in the past 12 months. These things are usually well planned ahead of time. So if that is true, now may be the time for those on the outside to also pick up cheap stock. However it is harder now to trust management! PC
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities